Lowest Price for Patients Act of 2024
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Lowest Price for Patients Act of 2024 (H.R. 8987) is a health policy bill introduced in the 118th Congress. The bill aims to address issues related to drug pricing to ensure patients have access to the lowest possible prices for medications. As of the latest update, the bill was referred to the Subcommittee on Health but did not advance further and ultimately failed or expired. The official summary and full text of the bill are not available, limiting detailed analysis of its provisions.
H.R. 8987 sought to improve patient access to affordable medications by focusing on lowest drug prices but did not progress beyond early committee referral and expired without enactment.
- The bill is focused on health policy, specifically drug pricing to benefit patients.
- It was introduced in the House during the 118th Congress and referred to the Subcommittee on Health.
- No official summary or full text is available, and the bill failed or expired without further legislative action.
['Patients seeking affordable prescription medications', 'Healthcare providers advocating for lower drug costs', 'Potentially health insurers and pharmacy benefit managers if pricing reforms affect their operations']
['Lack of available full text and official summary limits understanding of implementation details and enforcement mechanisms', 'Unclear funding sources or cost implications due to missing legislative text', 'Oversight and authority provisions cannot be assessed without full bill content']
The bill was introduced in the House of Representatives during the 118th Congress and referred to the Subcommittee on Health on December 17, 2024. It did not advance beyond this stage and was classified as failed or expired by July 21, 2025. The absence of detailed legislative text or summary suggests limited legislative momentum or prioritization.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could influence pharmaceutical pricing strategies and insurance coverage policies.', 'Potential downstream effects on healthcare costs and patient access to medications.', 'Changes in market dynamics for drug manufacturers and pharmacy benefit managers.']
Transparency is limited due to the absence of the bill's full text and official summary, which restricts comprehensive oversight and public understanding. The bill's failure to progress beyond subcommittee referral indicates limited legislative engagement. Future efforts would benefit from complete documentation to facilitate informed analysis and stakeholder input.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.